Tuesday, July 14, 2009

In Earnings Call, J&J Defends Tylenol, Talks Up Elan Deal

J&JJohnson & Johnson said this morning that its second quarter earnings fell 3.6% compared to the year-earlier period. The stock was up a bit in the first few hours of trading. For more on the numbers, see the earnings story from Dow Jones Newswires. The Health Blog listened in on the company's conference call, and we were struck by a few comments from CFO Dominic Caruso ...

No comments: